What’s the current market cap for Amylyx Pharmaceuticals, Inc. stock?

Amylyx Pharmaceuticals, Inc. (AMLX) has a market cap of $1.7bn as of June 17, 2026.

What is the P/E ratio for Amylyx Pharmaceuticals, Inc. stock?

The price to earnings (P/E) ratio for Amylyx Pharmaceuticals, Inc. (AMLX) stock is 0 as of June 17, 2026.

Does Amylyx Pharmaceuticals, Inc. stock pay dividends?

No, Amylyx Pharmaceuticals, Inc. (AMLX) stock does not pay dividends to its shareholders as of June 17, 2026.

When is the next Amylyx Pharmaceuticals, Inc. dividend payment date?

Amylyx Pharmaceuticals, Inc. (AMLX) stock does not pay dividends to its shareholders.

What is the beta indicator for Amylyx Pharmaceuticals, Inc.?

Amylyx Pharmaceuticals, Inc. (AMLX) has a beta rating of -0.1. This means that it has an inverse relation to market volatility.

Buy Amylyx Pharmaceuticals, Inc. stock | $AMLX Share Price

13:30

15:10

16:45

18:25

20:00

About Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.

Ticker

$AMLX

Sector

Health

Primary listing

NASDAQ

Employees

136

Headquarters

Cambridge, United States

Website

amylyx.com

AMLX Metrics

BasicAdvanced

$1.7bn

-$1.49

-0.10

Bulls say / Bears say

Enrollment is now complete for the pivotal Phase 3 LUCIDITY trial of avexitide, with topline results expected in Q3 2026. This positions Amylyx as a potential first-in-class therapy provider for post-bariatric hypoglycemia (EDGAR).

Avexitide received FDA Breakthrough Therapy Designation in March 2026 for post-bariatric hypoglycemia, which may speed up regulatory review and market launch (EDGAR).

The cash runway is expected to support operations through the potential commercial launch of avexitide and into 2028, reducing near-term financing risk (EDGAR).

Net loss increased to $41.3 million in Q1 2026 from $35.9 million in Q1 2025, reflecting a faster cash burn and growing pressure on liquidity (EDGAR).

Research and development expenses rose to $27.6 million in Q1 2026 from $22.1 million a year earlier, highlighting higher operating costs before reaching revenue-generating milestones (EDGAR).

The company’s value depends heavily on the results of the avexitide Phase 3 LUCIDITY trial, while other candidates like AMX0114 are still in Phase 1, exposing investors to binary trial risk (EDGAR).

Data summarised monthly by Lightyear AI. Last updated on 24 May 2026.

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $AMLX

Capital at risk

Market closed

Upcoming events

No upcoming events